

Cocirculation and replacement of SARS-CoV-2 variants in crowded settings and marginalized populations along the US-Mexico border

Antoine Chaillon, MD, PhD,⁽¹⁾ Ietza Bojorquez, MSc, PhD,⁽²⁾ Jaime Sepulveda, MPH, DSc,⁽³⁾ Alicia Yolanda Harvey-Vera, MD, PhD,^(1,4,5) M Gudelia Rangel, MPH, PhD,^(2,5) Britt Skaathun, MPH, PhD,⁽¹⁾ Sanjay R Mehta, MD,^(1,6) Caroline Ignacio, BSc,⁽¹⁾ Magali Porrachia, MS,⁽¹⁾ Davey M Smith, MD, MAS,^(1,6) Steffanie A Strathdee, PhD.⁽¹⁾

Chaillon A, Bojorquez I, Sepulveda J, Harvey-Vera AY, Rangel MG, Skaathun B, Mehta SR, Ignacio C, Porrachia M, Smith DM, Strathdee SA. Cocirculation and replacement of SARS-CoV-2 variants in crowded settings and marginalized populations along the US-Mexico border. *Salud Publica Mex.* 2022.

<https://doi.org/10.21149/13980>

Abstract

Objective. To interrogate the circulating SARS-CoV-2 lineages and recombinant variants in persons living in migrant shelters and persons who inject drugs (PWID). **Materials and methods.** We combined data from two studies with marginalized populations (migrants in shelters and persons who inject drugs) in Tijuana, Mexico. SARS-CoV-2 variants were identified on nasal swabs specimens and compared to publicly available genomes sampled in Mexico and California. **Results.** All but 2 of the 10 lineages identified were predominantly detected in North and Central America. Discrepancies between migrants and PWID can be explained by the temporal emergence and short time span of most of these lineages in the region. **Conclusion.** The results illustrate the temporo-spatial structure for SARS-CoV-2 lineage dispersal and the potential co-circulation of multiple lineages in high-

Chaillon A, Bojorquez I, Sepulveda J, Harvey-Vera AY, Rangel MG, Skaathun B, Mehta SR, Ignacio C, Porrachia M, Smith DM, Strathdee SA. Cocirculación y reemplazo de variantes de SARS-CoV-2 en espacios hacinados y poblaciones marginadas en la frontera México-EUA. *Salud Publica Mex.* 2022.

<https://doi.org/10.21149/13980>

Resumen

Objetivo. Investigar los linajes circulantes y variantes recombinantes de SARS-CoV-2 en migrantes en albergues y usuarios de drogas inyectables (UDI). **Material y métodos.** Se combinaron datos de dos estudios con poblaciones marginadas (migrantes en albergues y UDI) en Tijuana, México. Se identificaron variantes de SARS-CoV-2 en exudado nasal y se compararon con genomas disponibles públicamente de muestras de México y California. **Resultados.** Ocho de 10 linajes identificados se detectaron principalmente en Norte y Centro América. Las discrepancias entre migrantes y UDI se pueden explicar por la emergencia temporal y la corta duración de la mayoría de estos linajes en la región. **Conclusión.** Los resultados ilustran la estructura temporo-espacial de la dispersión de linajes de SARS-CoV-2, y la circulación posible de linajes múltiples en poblaciones en riesgo con contactos

- (1) Division of Infectious Diseases and Global Public Health, University of California San Diego. San Diego, United States.
- (2) Departamento de Estudios de Población, El Colegio de la Frontera Norte. Tijuana, Mexico.
- (3) Institute for Global Health Sciences, University of California. San Francisco, United States.
- (4) Facultad de Medicina, Universidad de Xochicalco. Tijuana, Mexico.
- (5) United States-Mexico Border Health Commission. Tijuana, Mexico.
- (6) Veterans Affairs Health System. San Diego, United States.

Received on: June 20, 2022 • **Accepted on:** October 13, 2022 • **Published online:** December 7, 2022
Corresponding author: Ietza Bojorquez. El Colegio de la Frontera Norte. Carretera Escénica Tijuana-Ensenada, San Antonio del Mar. 22560 Tijuana, Baja California, Mexico.
email: ietzabch@colef.mx

License: CC BY-NC-SA 4.0

risk populations with close social contacts. These conditions create the potential for recombination to take place in the California-Baja California border.

Keywords: SARS-CoV-2; lineages; recombination, genetic; drug users; emigrants and immigrants

sociales estrechos. Estas condiciones generan el potencial de recombinación en la frontera California-Baja California.

Palabras clave: SARS-CoV-2; linajes; recombinación genética; usuarios de drogas; migrantes

Mobility data can be used to predict the spread of SARS-CoV-2¹⁻³ and other viruses.⁴ The successive emergence of SARS-CoV-2 variants of concern (VOC) and their rapid spread around the world has highlighted the importance of genomic surveillance. For example, the B.1.1.529 variant aka 'Omicron' was first reported to the World Health Organization (WHO) from South Africa on 24 November 2021 and has been characterized by key mutations in the S protein, which play an integral role in viral transmission, immune evasion and virulence. Another mechanism for viral evolution is recombination. For recombination to occur, the parental lineages need to cocirculate in the same location to allow specific individuals to become coinfecting. This scenario provides the circumstances during which chimeric genotypes can emerge. For SARS-CoV-2, the first recombinant lineage in the Pango nomenclature system⁵ was designated as lineage XA after being identified in the UK. Since then, many other recombinants have been identified and led to limited or more global outbreaks. For example, XB variant⁶ (aka B.1.628), a recombinant lineage with parental lineage B.1.634 and B.1.631, was first identified in Mexico which also spread to the US, Guatemala, Honduras and El Salvador. The widespread circulation of lineage XB and other recombinants across multiple countries over an extended time span raised important questions regarding the role and potential effects of recombination on the evolution of SARS-CoV-2 during the ongoing Covid-19 pandemic.

The Covid-19 pandemic has disproportionately impacted socially marginalized populations.⁷ In this context, migrant populations living in temporary accommodations like camps and shelters may be at high risk for virus co-circulation and potential emergence of new VOC. Of particular concern are in-transit migrants, refugees, and asylum seekers, and those residing in camps and other overcrowded settings with limited access to resources for hygiene or physical distancing. Migrants in such settings typically have limited access to health-care, employment, and social services, and are therefore vulnerable to the social and economic impacts of lockdown and other measures.⁸⁻¹⁰ We recently reported that the prevalence of SARS-CoV-2 RNA positive samples among migrants to Tijuana living in shelters during 2021 was low (1.5%) but half (53.0%) were SARS-CoV-2

seropositive.¹¹ The high rate of social interactions within temporary accommodation and outside (e.g. in public transportation) and the mobility of these populations are important risk factors for cocirculation of different lineages and potential recombination.

Similarly, the Covid-19 pandemic has disproportionately impacted other vulnerable and marginalized communities, such as people who use drugs (PWUD).¹²⁻¹⁴ In a study of people who inject drugs (PWID) in Tijuana and San Diego, California conducted from 2020-2021, SARS-CoV-2 seroprevalence was 37%.¹⁵ Cross-border mobility and forced deportation has also been found to heighten vulnerability to a range of health and social harms in the Mexico-US border region, such as HIV and tuberculosis.¹⁶⁻²⁰

Herein, we report upon SARS-CoV-2 variants circulating in high risk and vulnerable populations of PWID and migrant populations living in temporary accommodations in the Mexico-US border region during the Covid-19 pandemic, and interrogate the cocirculation of these variants in Mexico and neighboring California.

Materials and methods

Cohort description and sampling

EPICO study. A non-probability survey of adult migrants aged ≥ 18 years living in shelters was conducted from November–December 2020 and February–April 2021. Participants (N=598) underwent interviewer-administered surveys in Spanish, English or French, and provided anterior nasal swabs for SARS-CoV-2 RNA testing.

La Frontera study. Between October 2020 and September 2021 PWID within the last month who were aged ≥ 18 years were recruited through community outreach in Tijuana (N=200) and San Diego (N=400). The Tijuana sample and half of the San Diego sample were required to reside in either city but report not having ever crossed the US-Mexico border to inject drugs, whereas the remaining half of the San Diego sample was required to have injected drugs in Mexico within the last two years. Participants underwent interviewer-administered surveys in Spanish or English and provided anterior nasal

swabs for SARS-CoV-2 RNA testing at enrolment and six months later.

Pre- and post-test counseling was provided following national guidelines in the U.S. and Mexico. For both studies, samples were batched and stored at -80 degrees Celsius and shipped weekly on dry ice for SARS-CoV-2 RNA detection.

SARS-CoV-2 detection and sequencing. Qualitative tests for SARS-CoV-2 were performed on all collected nasal swabs specimen for SARS-CoV-2 RNA detection using the FluxErgy platform (Irvine, CA, USA). SARS-CoV-2 full genome sequencing was performed using the Covid-19 ARTIC v4 Illumina library construction and sequencing protocol (https://github.com/CDCgov/SARS-CoV-2_Sequencing). Amplicons were generated with the NEBNext VarSkip VSS2b Primer kit (<https://github.com/nebiolabs/VarSkip>). PCR conditions were 98°C for 30s, followed by 35 cycles of 95°C for 15s and 63°C for 5 min. Libraries were generated with the NEBNext ARTIC SARS-CoV-2 FS Library prep kit (Illumina) with NEBNext Multiplex Oligos for Illumina. Samples were sequenced using a 2 x 75bp paired-end reads. Reads were processed with the CLC Genomics Workbench V22 (Qiagen). Briefly the workflow identifies individual SARS-CoV-2 sample variants by first trimming and mapping high quality reads (>20) to the reference genome and then calling variants to generate a full genome consensus for each sample.

Lineage identification and analyses. We used the Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) (version 1.1.14) command-line tool and Pango nomenclature system²¹ to determine the lineage of all SARS-CoV-2 genomes. Publicly available genomes sampled in Mexico and California from the lineages identified in the LF and EPICO cohorts were also retrieved from the Global Initiative on Sharing Avian Influenza Data (GISAID) database.²² We employed the Wuhan lineage as the reference to characterize the isolates.

Ethical considerations. These studies were reviewed and approved by the ethics committees of the University of California in San Diego (no. 201153), *El Colegio de la Frontera Norte* (no. 066-160720) and Xochicalco University. All participants gave written informed consent in their preferred language (Spanish, French or English).

Results

Cohort and sampling

EPICO study. Samples were collected from November to December 2020, and from February to April 2021. Of

598 samples, seven (1.2%) were confirmed positive by RT-PCR and six were successfully sequenced (figure 1A). **La Frontera study.** A total of 1 159 samples (1.4 [min-max: 1 -3] samples per participant on average) were collected between December 2020 to January 2022. Nine of the 1 159 (0.8%) tested positive and were sequenced (figure 1B).

SARS-CoV-2 genomic analysis


EPICO cohort. During the spring of 2021, three distinct lineages were detected (from March 27th to April 12th) (figure 2). All three were most detected in the US and Mexico. XB recombinant lineage (n=4)²³ was first identified in July 2020 and March 2021 in California and Mexico respectively and last reported in September and August 2021. The two other B1.627 and B1.631 lineages were also most common in in the US and Mexico followed by Central American countries and were not detected after August 2021 (tables I and II).^{5,22,24,25}

La Frontera cohort. Seven distinct lineages were identified from August 19th, 2021 (first detection), to January 2022 (figure 2). All but AY.42 (considered a large European [especially Spain] Delta sub-lineage) and BA.1.17.2 (sublineage of worldwide spread BA.1.17 lineage with S:701V) were also most frequently reported in North and Central America and co-circulated in California and Mexico in the summer / fall of 2021.

To interrogate the co-circulation of these lineages in the Mexico and neighboring California region we retrieved all full-length genomes available on GISAID.²² The spatial temporal distribution of these lineages in California and Mexico along with those from the EPICO and La Frontera cohort are presented in figure 3^{21,26} and under microreact project. A detailed summary of the distribution of these 10 SARS-CoV-2 lineages is provided in tables I and II^{5,22,24,25} and figure 3,^{21,26} along with timespan and cumulative prevalence in the United States, in Mexico and in California, and worldwide. Data can be visualized under microreact project (<https://microreact.org/project/auby4ddjtcyrfy3q3dxdds>).

Discussion

All but 2 of the 10 lineages reported in this study among PWID and migrants in shelters at the California-Mexico border were predominantly detected in North and Central America. The discrepancies between the two cohorts can be explained by the temporal emergence and short time span of most of these lineages in the region. Hence, the three lineages identified among migrants in shelters (EPICO study) were collected in



* Positive samples that were further sequenced are shown in red.

FIGURE 1. OVERVIEW OF WEEKLY SAMPLING FOR THE EPICO (A) AND LA FRONTERA (B) COHORT*

Table I
DATA FROM WEBPAGE COV-LINEAGE.ORG²⁴ RETRIEVED ON MAY 22 2022,
USING THE PANGOLIN NOMENCLATURE⁵

Lineage	N. sequences	Most common countries (%)	Earliest date	# designated	# assigned	Description
EPICO						
B.1.627	1	United States of America (72.0), Mexico (11.0), El Salvador (7.0), Honduras (5.0), Guatemala (4.0)	1/9/21	117	474	USA, Mexico and Honduras lineage, from pango-designation issue #130
B.1.634	1	United States of America (64.0), Mexico (34.0), Honduras (1.0), Guatemala (0.0), Panama (0.0)	3/2/21	71	289	Mexico and USA lineage, from pango-designation issue #159
XB	4	United States of America (77.0), Mexico (16.0), Guatemala (3.0), Honduras (2.0), El Salvador (1.0)	7/8/20	729	3 186	Recombinant lineage with parental lineages B.1.634 and B.1.631, Central and North America lineage, discussed in pango-designation issue #189. Formally B.1.628

(continues...)

(continuation)

La Frontera						
AY.100	2	United States of America (87.0), Mexico (4.0), India (1.0), Brazil (1.0), Canada (1.0)	7/16/20	16 627	86 622	Alias of B.1.617.2.100, USA lineage
AY.119	1	United States of America (95.0), Germany (1.0), Canada (1.0), United Kingdom (0.0), Dominican Republic (0.0)	10/29/20	2 356	35 639	Alias of B.1.617.2.119, USA lineage
AY.20	1	United States of America (58.0), Mexico (32.0), India (2.0), Germany (1.0), Colombia (1.0)	1/8/21	2 442	35 116	Alias of B.1.617.2.20, USA and Mexico lineage
AY.25.1	1	United States of America (55.0), Canada (40.0), Chile (2.0), Colombia (1.0), Aruba (0.0)	5/12/20	41 309	12 4153	Alias of B.1.617.2.25.1, Canada and USA lineage, from pango-designation issue #313
AY.42	2	Germany (19.0), Spain (17.0), France (15.0), Switzerland (7.0), Denmark (6.0)	10/15/20	14 252	26 326	Alias of B.1.617.2.42, European lineage, from pango-designation issue #239
AY.26	1	United States of America (83.0), Mexico (12.0), Brazil (1.0), Israel (0.0), Portugal (0.0)	1/7/21	5 011	43 878	Alias of B.1.617.2.26, USA and Mexico lineage, from pango-designation issue #188
BA.1.17.2	1	United Kingdom (71.0), United States of America (5.0), Canada (4.0), Germany (3.0), Denmark (3.0)	10/7/21	30 818	18 6393	Alias of B.1.1.529.1.17.2, lineage from pango-designation issue #462

Table II
LINEAGE ASSIGNMENT OF THE 15 GENOMES FROM THE EPICO (N=6) AND LA FRONTERA (N=9)
AND TIMESPAN OF SAMPLING DISTRIBUTION IN THE UNITED STATES, CALIFORNIA,
USA AND MEXICO. DATA FROM THE GISAID²²

Lineage	n	Location	Total	Cum. prevalence* %	First [‡]	Last [§]
EPICO						
B1.627	1	Mexico	51	< 0.5	4-Mar-21	21-Jul-21
		California, US	72	< 0.5	3-Feb-21	21-Jul-21
		United States	361	< 0.5	16-Jan-21	15-Aug-21
		Worldwide	493	< 0.5	9-Jan-21	21-Aug-21
B1.634	1	Mexico	96	< 0.5	9-Apr-21	30-Jul-21
		California, US	21	< 0.5	12-Apr-21	11-Aug-21
		United States	184	< 0.5	2-Mar-21	16-Aug-21
		Worldwide	284	< 0.5	27-Dec-20	16-Aug-21
X.B	4	Mexico	513	1	19-Mar-21	24-Aug-21
		California, US	876	< 0.5	8-Jul-20	15-Sep-21
		United States	2 627	< 0.5	8-Jul-20	9-Jan-22
		Worldwide	3 369	< 0.5	8-Jul-20	15-Feb-22
La Frontera						
AY100	2	Mexico	3 107	5	22-Sep-20	16-Feb-22
		California, US	12 480	2	31-Aug-20	29-Mar-22
		United States	80 611	3	31-Aug-20	29-Mar-22
		Worldwide	92 241	1	31-Aug-20	29-Mar-22

(continues...)

(continuation)

AY119	1	Mexico	19	< 0.5	2-Aug-21	17-Dec-21
		California, US	5 849	1	12-Jun-21	7-Feb-22
		United States	34 806	1	14-Jan-21	18-Apr-22
		Worldwide	36 777	< 0.5	29-Oct-20	18-Apr-22
AY.20	1	Mexico	11 271	20	21-Jan-21	20-Mar-22
		California, US	9 058	2	12-Apr-21	2-Feb-22
		United States	20 870	1	14-Jan-21	31-Mar-22
		Worldwide	35 985	< 0.5	14-Jan-21	31-Mar-22
AY.25.1	1	California, US	12 352	3	20-Apr-21	7-Feb-22
		Mexico	163	< 0.5	29-Jun-21	28-Feb-22
		United States	75 346	2	26-Dec-20	24-Mar-22
		Worldwide	134 23	1	11-Sep-20	28-Apr-22
AY.42	2	Mexico	14	< 0.5	11-Jul-21	20-Dec-21
		California, US	111	< 0.5	1-Jun-21	22-Dec-21
		United States	525	< 0.5	1-Jun-21	12-Jan-22
		Worldwide	28 786	< 0.5	15-Oct-20	11-Mar-22
AY26	1	Mexico	14	< 0.5	11-Jul-21	20-Dec-21
		California, US	111	< 0.5	1-Jun-21	22-Dec-21
		United States	525	< 0.5	1-Jun-21	12-Jan-22
		Worldwide	28 786	< 0.5	15-Oct-20	11-Mar-22
BA.1.17.2	1	Mexico	102	1	16-Dec-21	31-Mar-22
		California, US	1 230	1	1-Dec-21	29-Mar-22
		United States	11 155	< 0.5	31-Dec-20	27-Apr-22
		Worldwide	196 031	2	23-Oct-20	6-May-22

* Apparent cumulative prevalence is the ratio of the sequences containing B.1.627 to all sequences collected since the identification of B.1.627 in that location.

‡ Dates are based on the sample collection date; §genome key mutations from the outbreak.info²⁵

GISAID: Global Initiative on Sharing Avian Influenza Data

spring 2021. The lineages B1.627 and B1.634 emerged in March-April 2021 in both California and Mexico and were no longer detected worldwide after August 2021. Recombinant lineage X.B (originating from a recombination event between a B.1.631 major virus and a lineage B.1.634) was first reported in California during the summer 2020 but only in March 2021 in Mexico. While the widespread circulation of lineage XB across multiple countries lasted over a longer timespan worldwide, it was not reported after August/September 2021 in the region.

Seven distinct lineages were identified among PWID enrolled in the La Frontera cohort. These lineages were detected over a longer timespan than the previously mentioned lineages but all co-circulated in California and Mexico during 2021.

An important limitation of this observational study is that we had only a small number of isolates available for sequencing. Further larger scale studies would be

required to better determine the prevalence trajectories of these co-circulating variants. However, these results illustrate the temporo-spatial structure for SARS-CoV-2 lineage dispersal and the potential co-circulation of multiple lineages in high-risk populations with close social contacts, conditions for a recombination event to take place.

Considering the successful worldwide dispersal of recombinant XB, our study underscores the need for strengthening the screening, diagnosis, and prevention measures to these vulnerable populations. It also highlights the potential benefit of genomic sequencing data for quick and informed public health decisions (e.g. appropriate vaccine response) and the importance of communication and partnerships at the regional level. Further studies are necessary to explore the role and potential effects of recombination on the evolution of SARS-CoV-2 during the Covid-19 pandemic.




FIGURE 2. MONTHLY DISTRIBUTION OF THE 10 DISTINCT LINEAGES IDENTIFIED IN CALIFORNIA, MEXICO AND IN THE EPICO AND LA FRONTERA COHORT

Acknowledgments


We would like to thank the migrant shelters in Tijuana for facilitating this research, and the participants for generously contributing their time and experiences.

Data acknowledgements

We gratefully acknowledge the authors, originating and submitting laboratories of the genetic sequence and metadata made available through GISAID on which this research is based. A full acknowledgement table can be found with the following EPI_SET-IDs: EPI_SET_20220606sv (<https://doi.org/10.55876/gis8.220606sv>); EPI_SET_20220606fw (<https://doi.org/10.55876/gis8.220606fw>) and EPI_SET_20220606wx (<https://doi.org/10.55876/gis8.220606wx>) in Data Acknowledgement Locator under GISAID resources (<https://www.gisaid.org/>).

Funding

This research was funded by the American Academy of Arts and Sciences, Rethinking the Humanitarian Health Response to Violent Conflict project, the University of California, San Francisco and the San Diego Center for AIDS Research (CFAR), which is funded by the National Institutes of Health (P30 AI036214). AC is supported by the James B. Pendleton Charitable Trust and by the San Diego Center for AIDS Research (SD CFAR), an NIH-funded program (P30 AI036214), which is supported by the following NIH Institutes and Centers: NIAID, NCI, NHLBI, NIA, NICHD, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NIMHD, FIC, and OAR, the UCOP (R00RG2725) and by the NIH NIDA (R01DA055491). The study sponsors had no role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication.



A. Microreact²⁶ display of the geolocation of all genomes with associated lineage inferred by the Pangolin assignment tool.²¹ B. Distribution of the lineages in California, in Mexico and in the EPICO and La Frontera cohorts. C. Timeline of the 10 lineages. See also microreact project <https://microreact.org/project/uby4ddjtcyrfy3q3dxdds>

FIGURE 3. SPATIAL TEMPORAL DISTRIBUTION OF THE 10 LF/EPICO AND LA FRONTERA LINEAGES IN CALIFORNIA AND MEXICO

Declaration of conflict of interests. The authors declare that they have no conflict of interests.

References

1. Lemey P, Ruktanonchai N, Hong SL, Colizza V, Poletto C, Van den Broeck F, et al. Untangling introductions and persistence in COVID-19 resurgence in Europe. *Nature*. 2021;595(7869):713-7. <https://doi.org/10.1038/s41586-021-03754-2>
2. Kraemer MUG, Yang CH, Gutierrez B, Wu CH, Klein B, Pigott DM, et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science*. 2020;368(6490):493-7. <https://doi.org/10.1126/science.abb4218>
3. Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, et al. Spread of a SARS-CoV-2 variant through Europe in the summer

of 2020. *Nature*. 2021;595(7869):707-12. <https://doi.org/10.1038/s41586-021-03677-y>

4. Lemey P, Rambaut A, Bedford T, Faria N, Bielejec F, Baele G, et al. Unifying viral genetics and human transportation data to predict the global transmission dynamics of human influenza H3N2. *PLoS Pathog*. 2014;10(2):e1003932. <https://doi.org/10.1371/journal.ppat.1003932>
5. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol*. 2020;5(11):1403-7. <https://doi.org/10.1038/s41564-020-0770-5>
6. Gutierrez B, Castelan-Sanchez HG, Candido DDS, Jackson B, Fleishon S, Houzet R, et al. Emergence and widespread circulation of a recombinant SARS-CoV-2 lineage in North America. *Cell Host Microbe*. 2022;30(8):1112-23.e3. <https://doi.org/10.1016/j.chom.2022.06.010>
7. Upshaw TL, Brown C, Smith R, Perri M, Ziegler C, Pinto AD. Social determinants of COVID-19 incidence and outcomes: A rapid review. *PLoS One*. 2021;16(3):e0248336. <https://doi.org/10.1371/journal.pone.0248336>

8. Hayward SE, Deal A, Cheng C, Crawshaw A, Orcutt M, Vandrevala TF, et al. Clinical outcomes and risk factors for COVID-19 among migrant populations in high-income countries: A systematic review. *J Migr Health*. 2021;3:100041. <https://doi.org/10.1016/j.jmh.2021.100041>
9. Lebano A, Hamed S, Bradby H, Gil-Salmeron A, Dura-Ferrandis E, Garcés-Ferrer J, et al. Migrants' and refugees' health status and healthcare in Europe: a scoping literature review. *BMC Public Health*. 2020;20(1):1039. <https://doi.org/10.1186/s12889-020-08749-8>
10. Kondilis E, Papamichail D, McCann S, Orcutt M, Carruthers E, Veizis A, Hargreaves S. The impact of the COVID-19 pandemic on migrants, refugees and asylum Seekers in Greece: A retrospective analysis of national surveillance data from 2020. *eClinicalMedicine*. 2021;37:100958. <https://doi.org/10.1016/j.eclinm.2021.100958>
11. Bojorquez-Chapela I, Strathdee SA, Garfein RS, Benson CA, Chaillon A, Ignacio C, et al. The impact of the COVID-19 pandemic among migrants in shelters in Tijuana, Baja California, Mexico. *BMJ Global Health*. 2022;7(3):e007202. <https://doi.org/10.1136/bmjgh-2021-007202>
12. Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. *Diabetes Metab Syndr*. 2020;14(5):817-23. <https://doi.org/10.1016/j.dsx.2020.06.008>
13. Aponte-Melendez Y, Mateu-Gelabert P, Fong C, Eckhardt B, Kapadia S, Marks K. The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. *Harm Reduct J*. 2021;18(1):118. <https://doi.org/10.1186/s12954-021-00568-3>
14. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. *Mol Psychiatry*. 2021;26(1):30-9. <https://doi.org/10.1038/s41380-020-00880-7>
15. Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I, et al. Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. *PloS One*. 2021;16(11):e0260286. <https://doi.org/10.1371/journal.pone.0260286>
16. Deiss R, Garfein RS, Lozada R, Burgos JL, Brouwer KC, Moser KS, et al. Influences of cross-border mobility on tuberculosis diagnoses and treatment interruption among injection drug users in Tijuana, Mexico. *Am J Public Health*. 2009;99(8):1491-5. <https://doi.org/10.2105/ajph.2008.142166>
17. Melo JS, Mittal ML, Horyniak D, Strathdee SA, Werb D. Injection drug use trajectories among migrant populations: a narrative review. *Subs Use Misuse*. 2018;53(9):1558-70. <https://doi.org/10.1080/10826084.2017.1416404>
18. Goldenberg S, Silverman J, Engstrom D, Bojorquez-Chapela I, Strathdee S. "Right Here is the Gateway": Mobility, Sex Work Entry and HIV Risk Along the Mexico-U.S. Border. *Int Migr*. 2014;52(4):26-40. <https://doi.org/10.1111/imig.12104>
19. Strathdee SA, Lozada R, Ojeda VD, Pollini RA, Brouwer KC, Vera A, et al. Differential effects of migration and deportation on HIV infection among male and female injection drug users in Tijuana, Mexico. *PLoS One*. 2008;3(7):e2690. <https://doi.org/10.1371/journal.pone.0002690>
20. Strathdee SA, Lozada R, Pollini RA, Brouwer KC, Mantsios A, Abramovitz DA, et al. Individual, social, and environmental influences associated with HIV infection among injection drug users in Tijuana, Mexico. *J Acquir Immune Defic Syndr*. 2008;47(3):369-76. <https://doi.org/10.1097/QAI.0b013e318160d5ae>
21. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiol*. 2020;5(11):1403-7. <https://doi.org/10.1038/s41564-020-0770-5>
22. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill*. 2017;22(13):30494. <https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494>
23. Gutierrez B, Castelán-Sánchez HG, da Silva Candido D, Jackson B, Fleishon S, Ruis C, et al. Emergence and widespread circulation of a recombinant SARS-CoV-2 lineage in North America. *Cell Host Microbe*. 2022;30(8):1112-23. <https://doi.org/10.1016/j.chom.2022.06.010>
24. O'Toole Á, Hill V, Pybus OG, Watts A, Bogoch, Il, Khan K, et al. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with Grinch. *Wellcome Open Res*. 2021;6:121. <https://doi.org/10.12688/wellcomeopenres.16661.2>
25. Gangavarapu K, Latif A, Mullen J, Alkuzweny M, Hufbauer E, Tsung G, et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. 2022 [cited May 2022]. Available from: <https://outbreak.info/>
26. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, et al. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. *Microb Genom*. 2016;2(11). <https://doi.org/10.1099/mgen.0.000093>